Skip to content
Biodatica
Start free

Investigator

Artur Indzhykulian

MASSACHUSETTS EYE AND EAR INFIRMARY · funded by NIDCD

Companies
3

Resolved onto their grants.

Grants
3

Federal awards on file.

Non-dilutive funding
$1.8M

Summed across those awards.

First award
Jun 17, 2022

Latest Sep 11, 2025.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R21

    In-silico screen and in-vivo evaluation of FDA-approved drugs to treat noise-induced hearing loss

    $474k

    Sep 11, 2025NIDCDMASSACHUSETTS EYE AND EAR INFIRMARYNIH RePORTER · 11139658 (opens the source filing in a new tab)

  2. R01

    Development of Gene Therapy for Hereditary Deafness using Rational Protein Engineering

    $656k

    Jun 17, 2022NIDCDMASSACHUSETTS EYE AND EAR INFIRMARYNIH RePORTER · 11105969 (opens the source filing in a new tab)

  3. R01

    Development of Gene Therapy for Hereditary Deafness using Rational Protein Engineering

    $652k

    Jun 17, 2022NIDCDMASSACHUSETTS EYE AND EAR INFIRMARYNIH RePORTER · 11370142 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources